跳至主要内容
临床试验/NL-OMON51747
NL-OMON51747招募中3 期

Does colchicine reduce progression of aortic valve stenosis? - Colchicine and Inflammation in Aortic Stenosis (CHIANTI)

Radboud Universitair Medisch Centrum0 个研究点目标入组 150 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
入组人数
150

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • - Asymptomatic moderate aortic valve stenosis. The severity of AS will be
  • quantified according to current EACVI / ASE guidelines.

排除标准

  • Heavily calcified aortic valve on echocardiography (defined as grade 4
  • calcification: extensive thickening/calcification of all cusps as described in
  • the articles by Rosenhek et al.).
  • Severe mitral valve stenosis (MVA < 1cm2).
  • Severe mitral or aortic valve regurgitation.
  • Left ventricular dysfunction (LVEF < 35%).
  • Bicuspid aortic valve.
  • Rheumatic aortic valve disease.
  • Valvular disease due to history of chest radiation.
  • Patients aged <50 and >80 years.
  • Pre-existing chronic gastro-intestinal complaints which may obscure signs of
  • colchicine intolerance.
  • The presence of a pacemaker or internal cardiac defibrillator.
  • Child-bearing potential without the use of contraception.
  • Renal impairment (eGFR <30 ml/min/1.73m2).
  • Active or chronic liver disease.
  • A planned aortic valve replacement in the next six months.
  • Use of CYP3A4 (e.g. verapamil) or P-glycoprotein inhibitors.
  • Use of bisphosphonate or denosumab.
  • Chronic use of immunosuppressants or anti-inflammatory drugs including
  • colchicine and NSAID*s (excl. acetylsalicylic acid).
  • Life expectancy <2 years.

研究者

相似试验